Last updated: February 19, 2026

What is LIPOSYN 10% and its Current Market Position?

LIPOSYN 10% is an intravenous fat emulsion used as a nutritional substrate in parenteral nutrition. Its primary function is to provide essential fatty acids and calories to patients unable to consume food orally, critical for wound healing, immune function, and preventing essential fatty acid deficiency. The global market for parenteral nutrition, which includes lipid emulsions like LIPOSYN 10%, is experiencing steady growth driven by increasing incidences of chronic diseases, gastrointestinal disorders, and a rising elderly population requiring nutritional support. LIPOSYN 10% competes in a segment characterized by established players and a strong reliance on clinical adoption and hospital formulary inclusion. Key market drivers include the expanding healthcare infrastructure, advancements in parenteral nutrition formulations, and increasing demand for home-based parenteral nutrition solutions.

What are the Key Patents Protecting LIPOSYN 10%?

The intellectual property landscape surrounding LIPOSYN 10% is primarily defined by patents covering its formulation, manufacturing processes, and specific clinical applications. While the core composition of lipid emulsions has been known for decades, patents often focus on novel emulsification techniques, specific phospholipid compositions, particle size control, or improved stability and shelf-life.

Formulation Patents: These patents detail the specific ratios of soybean oil, egg phosphatides, and glycerin, along with other excipients, to achieve optimal stability and physiological compatibility. The precise method of emulsification and homogenization is often a subject of patent claims.
Manufacturing Process Patents: Innovations in the production of sterile, pyrogen-free lipid emulsions, including filtration methods, sterilization techniques, and quality control measures, can be protected.
Therapeutic Use Patents: While the broad use of lipid emulsions for nutritional support is established, patents may exist for specific indications, such as their use in particular patient populations (e.g., neonates with specific metabolic conditions) or in combination with other therapies.
Packaging and Delivery Patents: Improvements in the design of intravenous bags, administration sets, or multi-chamber bags for combined parenteral nutrition solutions that include lipid emulsions can also be patented.

Identifying the exact patent numbers and their expiry dates is crucial for competitive analysis and potential market entry strategies. Companies with expiring patents on key formulations or processes may face increased competition from generics or biosimilars, depending on regulatory pathways. Conversely, companies holding recent patents on improved formulations or novel applications can extend market exclusivity.

Who are the Key Manufacturers and Competitors for LIPOSYN 10%?

The market for intravenous fat emulsions is moderately concentrated, with several established pharmaceutical and nutritional companies holding significant market share. LIPOSYN 10% is manufactured and marketed by B. Braun Medical Inc. in the United States. Key competitors offer similar lipid emulsion products, often with varying compositions or indications.

B. Braun Medical Inc.: The primary manufacturer and marketer of LIPOSYN 10%. Their product portfolio in parenteral nutrition is extensive.
Baxter International Inc.: A major competitor offering a range of parenteral nutrition products, including Intralipid and Clinolipid, which are lipid emulsions.
Fresenius Kabi: Another significant player in the critical care and nutrition market, offering lipid emulsions like Smoflipid and Intralipid.
Hospira (now part of Pfizer): Historically a competitor with its own range of intravenous nutritional products.
Other Regional Manufacturers: Depending on the geographical market, smaller regional players may also offer competing lipid emulsion products.

The competitive landscape is characterized by intense brand loyalty within hospital systems, driven by established clinical data, formulary agreements, and supply chain reliability. Differentiation often comes from product purity, particle size distribution, and the availability of different lipid sources (e.g., soybean oil, medium-chain triglycerides, olive oil, fish oil).

What is the Financial Performance and Market Size for LIPOSYN 10%?

Quantifying the precise financial performance and market size solely for LIPOSYN 10% is challenging as financial reporting often aggregates sales data for entire product lines or therapeutic categories. However, the broader market for parenteral nutrition, which includes lipid emulsions, provides a strong indication of the sector's economic significance.

The global parenteral nutrition market was valued at approximately USD 7.9 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 5.8% from 2023 to 2030. This growth is underpinned by several factors:

Increasing Chronic Disease Prevalence: Conditions such as cancer, inflammatory bowel disease, and diabetes often necessitate parenteral nutrition.
Aging Global Population: Older adults are more susceptible to conditions requiring nutritional support.
Advancements in Medical Technology: Improved formulations and delivery systems enhance patient outcomes and expand the utility of PN.
Growing Demand for Home Parenteral Nutrition (HPN): HPN offers patients greater independence and improved quality of life, driving market expansion.

Within this market, lipid emulsions are a critical component, representing a substantial portion of the total market value. While specific revenue figures for LIPOSYN 10% are proprietary to B. Braun Medical Inc., its consistent presence in hospital formularies and its role as a foundational element of parenteral nutrition suggest it contributes significantly to the company's nutritional product segment. The market for intravenous fat emulsions is competitive, with pricing influenced by manufacturing costs, regulatory hurdles, and the presence of both branded and generic options.

What are the Regulatory and Approval Statuses for LIPOSYN 10%?

LIPOSYN 10% is approved by the U.S. Food and Drug Administration (FDA) for use as a nutritional substrate in the medical management of patients requiring parenteral nutrition. Its regulatory status is that of a prescription drug. The approval process for such products involves rigorous review of safety, efficacy, manufacturing quality, and labeling.

Key aspects of its regulatory journey and current status include:

FDA Approval: LIPOSYN 10% has undergone and passed the FDA's review for its intended use. The approval signifies that the benefits of the drug outweigh the risks for the indicated patient population.
Indication: Its primary indication is as a source of calories and essential fatty acids in patients receiving total parenteral nutrition (TPN).
Manufacturing Standards: B. Braun Medical Inc. must adhere to Current Good Manufacturing Practices (cGMP) as mandated by the FDA. This ensures consistent quality, purity, and potency of the product. Regular FDA inspections of manufacturing facilities are a standard part of maintaining compliance.
Labeling Requirements: The product labeling must include comprehensive information on indications, contraindications, warnings, precautions, adverse reactions, and dosage. This is a critical component of safe and effective drug use.
Post-Market Surveillance: Like all approved drugs, LIPOSYN 10% is subject to post-market surveillance to monitor for any unforeseen adverse events or safety concerns.
Generic Competition: The existence of generic or bioequivalent versions of lipid emulsions can impact market dynamics. However, the complexity of manufacturing sterile injectable products and the stringent regulatory requirements for equivalence can create barriers to entry for generic manufacturers.

The regulatory environment for parenteral nutrition products is stringent, requiring continuous compliance and adherence to evolving guidelines. Changes in manufacturing processes or formulation often necessitate regulatory review and approval.

What are the Future Market Trends and Opportunities for LIPOSYN 10%?

The future trajectory of LIPOSYN 10% and the broader lipid emulsion market will be shaped by several evolving trends and opportunities.

Advancements in Lipid Formulation: Research into novel lipid sources, such as olive oil, fish oil, and medium-chain triglycerides (MCTs), aims to provide tailored nutritional support with improved physiological benefits and reduced risks of complications like fatty liver disease. While LIPOSYN 10% is primarily soybean oil-based, innovations in this area could influence the competitive landscape and patient preferences.
Personalized Nutrition: The trend towards personalized medicine extends to nutrition. Future developments may involve lipid emulsions designed for specific patient profiles, considering factors like inflammatory status, metabolic needs, and genetic predispositions.
Improved Delivery Systems and Infusion Technologies: Innovations in admixture technologies, such as multi-chamber bags and ready-to-use formulations, enhance convenience, reduce medication errors, and improve the stability of parenteral nutrition admixtures.
Home Parenteral Nutrition Expansion: The continued growth of HPN services will drive demand for stable, easy-to-administer lipid emulsions. This segment offers significant growth potential for manufacturers with robust supply chains and support services.
Focus on Patient Outcomes and Cost-Effectiveness: Healthcare systems are increasingly focused on demonstrating value. Manufacturers that can provide robust clinical data supporting improved patient outcomes and cost-effectiveness will gain a competitive advantage.
Digital Health Integration: Technologies such as smart infusion pumps and remote patient monitoring could play a role in optimizing parenteral nutrition delivery and management, potentially influencing product choice.

While LIPOSYN 10% is a well-established product, its long-term market position will depend on its ability to remain competitive against newer formulations and its manufacturer's capacity to adapt to these evolving trends. Continued investment in manufacturing quality, supply chain resilience, and clinical support will be critical.

Key Takeaways

LIPOSYN 10% is a critical intravenous fat emulsion for parenteral nutrition, operating within a growing global market driven by chronic diseases and an aging population.
Its intellectual property is based on formulation and manufacturing process patents, with patent expiry dates being a key factor in competitive dynamics.
B. Braun Medical Inc. is the primary manufacturer of LIPOSYN 10%, facing competition from major players like Baxter and Fresenius Kabi.
The parenteral nutrition market, valued at approximately USD 7.9 billion in 2022, provides a strong proxy for the financial significance of lipid emulsions.
LIPOSYN 10% holds FDA approval for its indicated use, requiring adherence to strict cGMP manufacturing standards and post-market surveillance.
Future opportunities lie in novel lipid formulations, personalized nutrition, enhanced delivery systems, and the expanding home parenteral nutrition segment.

Frequently Asked Questions

What is the primary difference between LIPOSYN 10% and other lipid emulsions like Intralipid? LIPOSYN 10% is a specific formulation of soybean oil, egg phosphatides, and glycerin. Other lipid emulsions may differ in their lipid source (e.g., mixed oils like Smoflipid, olive oil-based like Clinolipid), particle size, or specific excipients, leading to variations in their physiological effects and clinical indications.
Are there any significant contraindications for LIPOSYN 10%? Yes, significant contraindications include severe hyperlipidemia, severe pancreatitis, and known hypersensitivity to egg or soy products.
What is the expected lifespan of patents related to LIPOSYN 10%'s core formulation? Patents for core pharmaceutical formulations typically last for 20 years from the filing date, with potential extensions through patent term restoration. However, the fundamental composition of basic lipid emulsions predates many modern patent filings. Specific patents often cover incremental improvements or manufacturing processes.
How does the cost of LIPOSYN 10% compare to its competitors? Pricing varies based on supply agreements, volume, and competitive pressures. While specific cost comparisons are proprietary, LIPOSYN 10% is generally priced competitively within the standard soybean oil-based lipid emulsion market.
What are the potential risks associated with long-term use of LIPOSYN 10%? Potential long-term risks include essential fatty acid deficiency if not adequately administered, hypertriglyceridemia, impaired immune function, essential fatty acid oversupply, and potential liver dysfunction. Close clinical monitoring is essential.

Citations

Global Parenteral Nutrition Market Size, Share & Trends Analysis Report By Product (Amino Acids, IV Fluids, Parenteral Nutrition, etc.), By Route of Administration (IV, IM, Subcutaneous), By End-use (Hospitals, Clinics, Homecare), By Region, And Segment Forecasts, 2023 - 2030. Grand View Research. (2023).
U.S. Food and Drug Administration. (n.d.). Orphan Drug Designation and Orphan Drug Exclusivity. Retrieved from [FDA website]
B. Braun Medical Inc. (2023). LIPOSYN 10%® Prescribing Information.
Clinical practice guidelines for the use of parenteral nutrition in the critically ill adult. American Society for Parenteral and Enteral Nutrition. (2017).
Parenteral Nutrition Market - Global Outlook and Forecast 2023-2028. Mordor Intelligence. (2023).

US Patents:	0
Applicants:	1
NDAs:	1
Clinical Trials:	4
DailyMed Link:	LIPOSYN 10% at DailyMed

Sponsor	Phase
The Cleveland Clinic	Early Phase 1
Pennington Biomedical Research Center	Early Phase 1
The University of Texas Health Science Center at San Antonio	N/A

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbott	LIPOSYN 10%	safflower oil	INJECTABLE;INJECTION	018203-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

LIPOSYN 10% Drug Patent Profile

When do Liposyn 10% patents expire, and when can generic versions of Liposyn 10% launch?

AI Deep Research

Questions you can ask:

Summary for LIPOSYN 10%

Recent Clinical Trials for LIPOSYN 10%

US Patents and Regulatory Information for LIPOSYN 10%

LIPOSYN 10% Market Dynamics and Financial Trajectory